Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00359359
Status:
COMPLETED
Last Update Posted:
2014-11-04
First Post:
2006-07-27
Brief Title:
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Phase III Study to Investigate the Safety Tolerability Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease ED Stage Small-cell Lung Cancer SCLC
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine whether the study drug ZK 219477 also known as SH Y03757A combined with cisplatin is effective in the treatment of small cell lung cancer in patients who did not receive prior treatment for their lung cancer
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG GermanyBayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-000067-29 | EUDRACT_NUMBER | None | None |
| 310101 | OTHER | Company Internal | None |